作者
Vrishali S Salian, Jessica A Wright, Peter T Vedell, Sanjana Nair, Chenxu Li, Mahathi Kandimalla, Xiaojia Tang, Eva M Carmona Porquera, Krishna R Kalari, Karunya K Kandimalla
发表日期
2021/1/19
来源
Molecular pharmaceutics
卷号
18
期号
3
页码范围
754-771
出版商
American Chemical Society
简介
At the stroke of the New Year 2020, COVID-19, a zoonotic disease that would turn into a global pandemic, was identified in the Chinese city of Wuhan. Although unique in its transmission and virulence, COVID-19 is similar to zoonotic diseases, including other SARS variants (e.g., SARS-CoV) and MERS, in exhibiting severe flu-like symptoms and acute respiratory distress. Even at the molecular level, many parallels have been identified between SARS and COVID-19 so much so that the COVID-19 virus has been named SARS-CoV-2. These similarities have provided several opportunities to treat COVID-19 patients using clinical approaches that were proven to be effective against SARS. Importantly, the identification of similarities in how SARS-CoV and SARS-CoV-2 access the host, replicate, and trigger life-threatening pathological conditions have revealed opportunities to repurpose drugs that were proven to be …
引用总数
学术搜索中的文章